Ascentage Pharma Group International (NASDAQ:AAPG) Stock Gets Price Target Cut from JPMorgan Chase & Co.

Posted by Linda Flegge on Oct 11th, 2026

Ascentage Pharma Group International (NASDAQ:AAPG – Free Report) had its price target reduced by JPMorgan Chase & Co. from $46.00 to $33.00 in a report issued on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other research firms have also weighed in on AAPG. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock. BTIG Research reiterated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Finally, Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Two equities research analysts have rated the stock with a Strong Buy rating and nine have given a Buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $44.75.

Get Our Latest Analysis on Ascentage Pharma Group International

Ascentage Pharma Group International Stock Performance

Shares of NASDAQ:AAPG opened at $14.63 on Thursday. The business has a 50 day moving average price of $16.71 and a 200 day moving average price of $19.34. Ascentage Pharma Group International has a twelve month low of $14.45 and a twelve month high of $37.50. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million for the quarter. As a group, equities analysts predict that Ascentage Pharma Group International will post -2.42 EPS for the current fiscal year.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.